NO20061167L - Kombinasjonen av en serotonin-reopptaksinhibitor og en glysintransporter type 1-inhibitor for behandling av depresjon - Google Patents

Kombinasjonen av en serotonin-reopptaksinhibitor og en glysintransporter type 1-inhibitor for behandling av depresjon

Info

Publication number
NO20061167L
NO20061167L NO20061167A NO20061167A NO20061167L NO 20061167 L NO20061167 L NO 20061167L NO 20061167 A NO20061167 A NO 20061167A NO 20061167 A NO20061167 A NO 20061167A NO 20061167 L NO20061167 L NO 20061167L
Authority
NO
Norway
Prior art keywords
inhibitor
serotonin reuptake
disorders
depression
treatment
Prior art date
Application number
NO20061167A
Other languages
English (en)
Norwegian (no)
Inventor
Jorn Arnt
Michael Didriksen
Sandra Hogg Willigers
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of NO20061167L publication Critical patent/NO20061167L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Nutrition Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20061167A 2003-08-21 2006-03-13 Kombinasjonen av en serotonin-reopptaksinhibitor og en glysintransporter type 1-inhibitor for behandling av depresjon NO20061167L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49673803P 2003-08-21 2003-08-21
DKPA200301198 2003-08-21
PCT/DK2004/000547 WO2005018676A1 (en) 2003-08-21 2004-08-18 The combination of a serotonin reuptake inhibitor and a glycine transporter type 1 inhibitor for the treatment of depression

Publications (1)

Publication Number Publication Date
NO20061167L true NO20061167L (no) 2006-03-13

Family

ID=34219531

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20061167A NO20061167L (no) 2003-08-21 2006-03-13 Kombinasjonen av en serotonin-reopptaksinhibitor og en glysintransporter type 1-inhibitor for behandling av depresjon

Country Status (12)

Country Link
US (1) US20060223857A1 (is)
EP (1) EP1660130A1 (is)
JP (1) JP2007502785A (is)
KR (1) KR20060066729A (is)
CN (1) CN1867358A (is)
AU (1) AU2004266057A1 (is)
BR (1) BRPI0413587A (is)
CA (1) CA2536275A1 (is)
IS (1) IS8277A (is)
MX (1) MXPA06002002A (is)
NO (1) NO20061167L (is)
WO (1) WO2005018676A1 (is)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100457738C (zh) * 2001-12-20 2009-02-04 H·隆德贝克有限公司 芳氧基苯基和芳硫基苯基衍生物
US8604080B2 (en) * 2007-02-14 2013-12-10 W. Louis Cleveland High dose glycine as a treatment for obsessive-compulsive disorder and obsessive compulsive spectrum disorders
CN101338337B (zh) * 2007-07-04 2011-11-02 北京华安佛医药研究中心有限公司 多态性位点基因型预测抑郁症及药效的用途、方法和试剂盒
EP2380595A1 (en) 2010-04-19 2011-10-26 Nlife Therapeutics S.L. Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types
CN102949364A (zh) * 2011-08-30 2013-03-06 天津药物研究院 一种含有效成分盐酸维拉佐酮的缓释片
EP3870292A4 (en) 2018-10-26 2022-11-09 The Research Foundation for The State University of New York COMBINATION OF SEROTONIN-SPECIFIC RESUPPUT INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000501707A (ja) * 1995-12-07 2000-02-15 ジャビット，ダニエル・シー グリシン捕捉性アンタゴニストを用いる拒絶性および認知性精神分裂病症候群の処置
US6361957B1 (en) * 1999-08-03 2002-03-26 Glytech, Inc. Assay for D-serine transport antagonist and use for treating psychosis
CZ294348B6 (cs) * 1996-05-31 2004-12-15 Allelix Neuroscience Inc. Substituovaný derivát glycinu a farmaceutický prostředek s jeho obsahem
US6117855A (en) * 1996-10-07 2000-09-12 Merck Sharp & Dohme Ltd. Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
GB2336534A (en) * 1998-04-24 1999-10-27 Alec James Coppen Anti-depressant - Folic Acid Combination
DOP2001000189A (es) * 2000-06-30 2002-03-30 Pfizer Prod Inc Benzofenonas y sulfonas como inhibidores de la captación de glicina
CZ2003396A3 (cs) * 2000-07-21 2003-05-14 H. Lundbeck A/S Inhibitory transportu glycinu
CN100457738C (zh) * 2001-12-20 2009-02-04 H·隆德贝克有限公司 芳氧基苯基和芳硫基苯基衍生物
US20050288355A1 (en) * 2002-06-20 2005-12-29 Arne Mork Combination therapy wherein a serotonin reuptake inhibitor is used
MXPA05012493A (es) * 2003-05-27 2006-05-25 Forest Laboratories Combinacion de un antagonista del receptor de nmda y un inhibidor selectivo de reabsorcion de serotonina para el tratamiento de depresion y otros trastornos de estado de animo.

Also Published As

Publication number Publication date
WO2005018676A1 (en) 2005-03-03
CA2536275A1 (en) 2005-03-03
CN1867358A (zh) 2006-11-22
MXPA06002002A (es) 2006-05-17
BRPI0413587A (pt) 2006-10-17
IS8277A (is) 2006-01-31
US20060223857A1 (en) 2006-10-05
JP2007502785A (ja) 2007-02-15
AU2004266057A1 (en) 2005-03-03
EP1660130A1 (en) 2006-05-31
KR20060066729A (ko) 2006-06-16

Similar Documents

Publication Publication Date Title
NO20100333L (no) Behandling av nevrotiske forstyrrelser
SE0301010D0 (sv) Novel compounds
NO20060402L (no) 3-amino choman og 2-aminotetralinderivater
ATE411280T1 (de) Phenoxyessigsäure-derivate zur behandlung von störungen der atemwege
DE60119534D1 (de) Verwendung von hydroxyethylrutosiden zur behandlung von erkältungssymptomen, symptomen der allergischen rhinitis und atemwegsinfektionen
UA82828C2 (en) The use of enantiomeric pure escitalopram for treatment of depression
NO20055202L (no) Hoykonsentrasjonsantistoff og proteinformuleringer
NO20082026L (no) Deazapuriner som er nyttige som inhibitorer for Janus-kinaser
HRP20180098T1 (hr) Kombinacije koje obuhvaćaju brekspiprazol ili jednu njegovu sol i jedan drugi lijek za uporabu u liječenju cns-poremećaja
NO20082679L (no) Sammensetning og fremgangsmate for a behandle CNS lidelser
DE602007014206D1 (de) Neuartige serotonin-wiederaufnahmehemmer als arzneimittel mit peripheriesystem-beschränkter aktivität
EE200400005A (et) Tablett, mis sisaldab vähemalt kahte eristatavat segmenti ning selle kasutamine
NO20045552L (no) Kombinasjonsterapi hvori en serotonin gjenopptaksinhibitor anvendes
NO20082203L (no) Fremgangsmater for a behandle sentralnervesystemforstyrrelser med en lavdosekombinasjon av escitalopram og bupropion
ATE432278T1 (de) Verbindungen zur behandlung von krankheiten
NO20053810L (no) Thiofenkarboksamider som inhibitorer av enzymet IKK-2
JP2007513052A5 (is)
NO20063267L (no) Kombinasjonen av en serotonin-reopptaksinhibitor og en histamin 3-reseptorantagonist, invers agonist eller partiell agonist
DE502004006525D1 (de) Verwendung von feigenkaktus (opuntia) zur herstellung eines medikaments zur behandlung von depressionen
BRPI0413587A (pt) usos de um composto e de um inibidor de glyt-1, composição farmacêutica, kit, e, método para o tratamento de doença
NO20082201L (no) Stabile farmasoytiske formuleringer inneholdende escitalopram og bupropion
MX2024014447A (es) Compuestos
AR048134A1 (es) La combinacion de un inhibidor de la recaptacion de serotonina y un antagonista del receptor de la histamina 3, el agonista inverso o el agonista parcial
WO2007070840A3 (en) Modified and pulsatile release pharmaceutical formulations of escitalopram
EA200600453A1 (ru) Комбинация ингибитора обратного захвата серотонина и ингибитора переносчика глицина типа 1 для лечения депрессии

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: PLOUGMANN & VINGTOFT, POSTBOKS 1003 SENTRUM, 0104